These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36793287)

  • 1. Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study.
    Huang Y; Dong S; Wang C; Dong Z; Chen W
    Front Endocrinol (Lausanne); 2023; 14():1090598. PubMed ID: 36793287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHOULD ROUTINE LIVER BIOPSY BE CONSIDERED IN BARIATRIC SURGICAL PRACTICE? AN ANALYSIS OF THE LIMITATIONS OF NON-INVASIVE NAFLD MARKERS.
    Concon MM; Gestic MA; Utrini MP; Chaim FDM; Chaim EA; Cazzo E
    Arq Gastroenterol; 2022; 59(1):110-116. PubMed ID: 35442320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery.
    Udelsman BV; Corey KE; Lindvall C; Gee DW; Meireles OR; Hutter MM; Chang DC; Witkowski ER
    Surg Obes Relat Dis; 2019 Jun; 15(6):843-849. PubMed ID: 31014948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease.
    Schwenger KJP; Alali M; Ghorbani Y; Fischer SE; Jackson TD; Okrainec A; Allard JP
    Obes Surg; 2023 Jan; 33(1):247-255. PubMed ID: 36464738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
    Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
    Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures.
    Udelsman BV; Corey K; Hutter MM; Chang DC; Witkowski ER
    Surg Obes Relat Dis; 2021 Feb; 17(2):292-298. PubMed ID: 33153965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
    Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
    Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.